Rybelsus® (oral semaglutide) approved for the treatment of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
59
Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU

Bagsværd, Denmark, 4 April 2020 - Novo Nordisk today announced that the European Commission (EC) has granted marketing authorisation for Rybelsus ® (oral semaglutide), for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise. The marketing authorisation applies to all 27 European Union member states and the United Kingdom.

Rybelsus ® is the first and only oral glucagon-like-peptide-1 (GLP-1) receptor agonist. The approval is based on the results from 10 PIONEER clinical trials, in which Rybelsus ® after 52 weeks demonstrated statistically significant reductions in HbA 1c vs sitagliptin, empagliflozin and liraglutide and with up to 4.3 kg weight reduction. Across the PIONEER programme, Rybelsus ®  demonstrated a safe and well-tolerated profile, with the most common adverse event being mild to moderate nausea which diminished over time.

“We are very excited about the approval of Rybelsus ® as we can now offer people in Europe living with type 2 diabetes the first and only GLP-1 in a tablet,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer. “Based on its strong clinical profile, we believe Rybelsus ® has the potential to set a new standard for the treatment of type 2 diabetes, as millions of people are currently not achieving target blood sugar levels on available oral antidiabetic medications.”

The launch of Rybelsus ® is expected to take place in the first EU countries in the second half of 2020.

About Rybelsus ®                                                                                         

Rybelsus ® (oral semaglutide) is an analogue of the naturally occurring hormone GLP-1. Rybelsus ® is approved in the US, Switzerland and EU as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is administered once daily and is approved for use in two therapeutic dosages, 7 mg and 14 mg.

Rybelsus ® is currently under review by several regulatory agencies, including the Japanese Pharmaceuticals and Medical Devices Agency.

Further information

Media:    
Mette Kruse Danielsen +45 3079 3883 mkd@novonordisk.com
Ken Inchausti (US) +1 609 240 9429 kiau@novonordisk.com
     
Investors:    
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com
Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
Mark Joseph Root +45 3079 4211 mjhr@novonordisk.com
Kristoffer Due Berg (US) +1 609 235 2989 krdb@novonordisk.com

Company announcement No 21 / 2020

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 173

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 0

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Volta M100 Puts Flexibility at Pad Printing's Center

Updated Category News Views 43

A tabletop printer rarely earns a second glance, but the Volta M100 is making a sensible argument: small manufacturers do not need another rigid box that becomes obsolete the minute a job changes. Boston Industrial Solutions has introduced the Volta M100 as a pad-printing machine built around adjustability, operator convenience, and software that can be upgraded as...

Continue Reading
Broadridge Brings Boyman In to Sharpen Its Market Story

Updated Category News Views 44

Financial plumbing rarely gets applause, which is precisely why Broadridge needs somebody who can explain its value without turning the pitch into alphabet soup. Lauren Boyman arrives as chief marketing and communications officer on November 23, taking charge of global marketing, corporate communications, product positioning, digital strategy, lead generation and thought...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 44

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
UN Integrity Accelerator Targets Corporate Corruption

Updated Category News Views 84

Corruption rarely arrives wearing a villain costume; it shows up as a rushed payment, a friendly intermediary, or a contract nobody wants examined too closely. That is why the United Nations Global Compact's new Business Integrity Accelerator deserves a sober look. Launched November 18, 2026, the programme is not a magic shield, and nobody should sell it as one. But it...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 0

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 178

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 0

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 26

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading

Top 5 Most Recently Viewed Articles

Charlotte's Web Moves Forward with AJA001 Autism Treatment Trial

Updated Category News Views 280

Charlotte's Web Progresses to Phase 2 in Autism Treatment Charlotte's Web Holdings, Inc. (TSX: CWEB) has announced an important step in the development of its botanical drug known as AJA001, aimed at treating symptoms associated with autism spectrum disorder (ASD). The U.S. Food and Drug Administration (FDA) has officially issued a green light for Charlotte's Web and its...

Continue Reading
Uptown Cheapskate and Kid to Kid Celebrate Monumental Growth

Updated Category News Views 257

Uptown Cheapskate and Kid to Kid Celebrate Monumental Growth Uptown Cheapskate and Kid to Kid have reached an amazing milestone, surpassing $300 million in system-wide sales during a recent year, showcasing a remarkable growth of over 20% compared to the previous year. This achievement is a testament to the increasing consumer demand for thrift shopping and the unique...

Continue Reading
Exploring the Thriving Landscape of Smart Wearables Market Trends

Updated Category News Views 146

Overview of the Smart Wearables Market Growth The Smart Wearables market is on an exciting upward trajectory, expected to surge from its valuation of USD 77.95 billion to an impressive USD 319.42 billion by 2032. With a robust compound annual growth rate (CAGR) of 19.34%, the sector reflects significant consumer interest and technological advancements. This remarkable...

Continue Reading
Exciting Partnership: Bass Pro Shops and the SMX League Unite

Updated Category News Views 239

Bass Pro Shops Teams Up With The SMX League Bass Pro Shops is set to become the official partner across the entire SMX racing calendar. One of the most thrilling events to look forward to is the Monster Energy SMX World Championship Final, which is scheduled to take place at Thunder Ridge, creating an exciting experience for fans. Venue Selection for The Championship...

Continue Reading
ADI Foundation Launches Innovative ADI Chain Mainnet and Token

Updated Category News Views 172

Exciting Developments from the ADI Foundation The ADI Foundation has recently launched the mainnet of ADI Chain along with its native ADI utility token. This significant step establishes a specialized Layer-2 blockchain aimed at enhancing operations for governments, regulated entities, and various real-world applications. By creating a tailored blockchain environment, the...

Continue Reading